Stock Availability And Delivery For Both Treatments
Mounjaro And Wegovy Stock Availability Across The UK
The weight management landscape has been transformed by consistent availability of both Mounjaro and Wegovy through EverydayMeds' reliable supply chain. Unlike the historical shortages that affected Wegovy supply throughout 2022 and early 2023, our GPhC-registered pharmacy (#9012878) maintains consistent stock levels across all five Wegovy doses and Mounjaro's six dose strengths. This reliability stems from our direct relationships with Novo Nordisk and Eli Lilly, ensuring patients can access their prescribed medication without interruption.
Both Mounjaro and Wegovy arrive via temperature-controlled delivery, maintaining the 2-8°C storage requirements essential for medication efficacy. Our pharmacy team monitors stock levels daily, with automated reordering systems preventing the supply gaps that previously frustrated patients seeking these prescription-only medicines. Whether you're starting treatment or maintaining your current dose, both options remain consistently available for immediate dispatch.
Mounjaro And Wegovy Pricing With Transparent Bundle Options
Wegovy pricing starts at £79.99 for the 0.25mg starter dose, progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), and £209.99 for the 2.4mg maintenance dose. Our Getting Started bundles provide convenient pairing options, such as the Intro Duo (0.25mg & 0.5mg) for £169.99, eliminating multiple ordering sessions during dose escalation. Mounjaro follows its own pricing structure, with both medications requiring the same clinical oversight and prescription process.
Bundle pricing reflects convenience rather than cost savings, ensuring patients can secure multiple months of supply through single transactions. The Ultimate Stability Trio provides three months of 2.4mg Wegovy maintenance doses for £649.99, ideal for patients established on their target dose. New customers apply code FIRST40 at checkout, whilst returning customers use DOSE25, with both codes factored into our displayed pricing structure.
Clinical Evidence Supporting Mounjaro And Wegovy Effectiveness
The STEP clinical trial programme demonstrated Wegovy's efficacy, with STEP 1 showing participants achieved approximately 15% average weight loss at 68 weeks when combined with lifestyle interventions (Wilding et al., NEJM, 2021). The SELECT cardiovascular outcomes trial further revealed a 20% reduction in major cardiovascular events amongst participants taking semaglutide. These results reflect carefully controlled clinical conditions and may not represent individual outcomes.
Mounjaro's SURMOUNT trials indicated the dual GIP and GLP-1 receptor agonist mechanism may offer distinct benefits, though direct head-to-head comparisons between Mounjaro and Wegovy remain limited due to different trial designs and participant populations. Both medications require prescription through clinical assessment, with individual responses varying based on numerous factors including adherence, lifestyle modifications, and metabolic differences.
Understanding How Wegovy And Mounjaro Work Differently
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the natural incretin hormone GLP-1, which signals satiety to the brain after meals. This mechanism reduces appetite, promotes feelings of fullness with smaller portions, and may diminish food cravings by acting on brain appetite centres. Mounjaro utilises tirzepatide, which activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, creating a dual agonist approach. The GIP component may enhance insulin sensitivity and provide additional metabolic benefits beyond appetite regulation. Both mechanisms support weight management when combined with reduced-calorie diets and increased physical activity, though individual responses vary significantly between patients.
Streamlined Ordering Process For Mounjaro And Wegovy
Our clinical assessment takes approximately three minutes, covering medical history, current medications, and weight management goals to determine suitability for either Mounjaro or Wegovy. Qualified prescribers review applications within three working days (or 24 hours with express service), ensuring appropriate medication selection and dosing recommendations. Once approved, medications dispatch via next-day delivery using specialised cold-chain packaging that maintains the required 2-8°C temperature throughout transit. Tracking information provides real-time updates, whilst our pharmacy team remains available for any questions during the process. Both Mounjaro and Wegovy arrive ready for immediate use, with comprehensive injection instructions and dosing schedules included in every package.
Storage Requirements And Practical Considerations
Both Mounjaro and Wegovy require refrigerated storage at 2-8°C before first use, though Wegovy offers superior travel flexibility with six weeks of room temperature stability (below 30°C) compared to Mounjaro's 21-day limit. The FlexTouch pen design used for Wegovy provides intuitive injection delivery, whilst Mounjaro employs its own pre-filled pen system. Dose escalation schedules differ between the medications, with Wegovy following a five-step progression over 16 weeks to reach the 2.4mg maintenance dose. Both treatments require once-weekly injection, typically administered on the same day each week. Patients should rotate injection sites between thigh, abdomen, and upper arm to minimise local irritation, with proper pen disposal following local pharmaceutical waste guidelines.
Comparing Mounjaro And Wegovy Availability During Seasonal Demand
Seasonal fluctuations in weight management medication demand typically peak during January and pre-summer months, historically creating supply pressures for both Mounjaro and Wegovy. Our inventory management system anticipates these patterns, maintaining higher stock levels during anticipated surge periods. Unlike single-medication pharmacies that may experience shortages during peak demand, our dual-supply capability for both treatments provides patients with alternatives should temporary supply constraints affect either manufacturer.
Both Mounjaro and Wegovy remain equally effective for appropriate candidates, with prescriber guidance helping determine optimal medication selection based on individual patient factors rather than availability concerns. Our stock monitoring includes real-time manufacturer updates, ensuring patients receive accurate availability information before completing their clinical assessment.
Securing Your Mounjaro Or Wegovy Supply Today
Both Mounjaro and Wegovy are immediately available through EverydayMeds, eliminating the uncertainty that previously characterised weight management medication access. New customers can begin their clinical assessment using code FIRST40, whilst existing patients benefit from DOSE25 pricing. Our GPhC-registered pharmacy (#9012878) ensures medication authenticity and proper handling throughout the supply chain. Visit https://everydaymeds.co.uk/collections/wegovy to start your assessment today. Whether you choose Mounjaro's dual-agonist approach or Wegovy's established GLP-1 mechanism, both prescription-only medicines are ready for immediate dispatch with next-day delivery. Our experienced prescribers can help determine which treatment aligns with your weight management goals and medical history.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
